Shanghai Medicilon Inc.

Liposomal drugs, as a major breakthrough in modern medicine, not only significantly enhance drug solubility, stability, and bioavailability but also greatly reduce toxic side effects on healthy tissues. From cancer treatment to vaccine delivery and gene therapy, the applications of liposomal drugs are vast and promising. However, this cutting-edge therapeutic approach also brings unique challenges. The bioanalysis of liposomal drugs is a complex and critical process, involving structural analysis, stability studies, and pharmacokinetics, among other aspects. How can we overcome these challenges? How can we address various difficulties in practice? The Cloud Lecture Hall has invited a senior scientific research expert in the field of liposomes, Sai Lian, who will provide an in-depth analysis of the practical challenges in the bioanalysis of liposomal drugs, drawing on extensive experience and unique insights Q1. How to choose the appropriate SPE plate during the method development stage

Medicilon has established an innovative, flexible, and reliable Large Animal Pharmacodynamic Research Service Platform that focuses on large animal models such as non-human primates, dogs, rabbits, and miniature pigs. The platform not only offers standard disease model development services but is also skilled in customizing complex disease models to meet the diverse research needs of clients.  In addition, the platform provides a full range of services from drug screening and efficacy evaluation to safety assessment, helping clients accelerate the new drug development process. With the advent of the era of precision medicine and the deepening understanding of disease mechanisms, large animal models such as non-human primates, dogs, rabbits, and miniature pigs have shown unique advantages and value in key areas of drug development. Due to their higher physiological similarity to humans, these models are particularly valuable in the research of cardiovascular diseases, metabolic disorde

  Recently, Shanghai Medicilon Inc. (Medicilon) has successfully obtained an invention patent from the National Intellectual Property Administration for its self-developed project titled "Antibodies Targeting Nectin-4 and Their Various Applications"! The successful granting of this patent not only recognizes Medicilon's deep expertise and technical strength in the field of cancer antibody drug development but also enriches its technological reserves. This advancement provides cutting-edge technical support and service assurance to enhance the drug development efforts of its clients. Nectin-4 Target: A Rising Star in Tumor Therapy, Offering New Hope for Various Cancer Treatments Nectin-4 Structure (Image Source: Nature Drug Discovery) Nectin-4 is a protein encoded by the poliovirus receptor-related 4 (PVRL-4) gene. It is an immunoglobulin-like protein that does not depend on Ca2+ for its function.  Nectin-4 interacts with other adhesion proteins such as Nectin-1, Nectin-2,